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A 10 centre calibration was performed after six years to
determine the international sensitivity index (ISI) of rTF/95
relative to RBT/90, and to assess any international normal-
ised ratio (INR) bias compared with the original multicentre
calibration. After exclusion of one outlying centre, the follow
up calibration gave a mean ISI for rTF/95 of 0.99, which
although a small difference, is significantly greater than the
mean ISI of 0.94 obtained previously. The change in ISI for
international reference preparation (IRP) rTF/95 relative to
RBT/90 would lead to a slight bias in INR for human
compared with rabbit thromboplastins. At a theoretical
INR of 3.0, the INR bias is 6.0%, and this is below the
accepted 10% level of clinical relevance. Ongoing stability
monitoring of World Health Organisation thromboplastin IRP
is advised.
T
he World Health Organisation (WHO) prothrombin time
(PT) standardisation scheme derives from a mathema-
tical determination of the responsiveness of individual
PT test systems. The manual PT results with a thromboplastin
international reference preparation (IRP) are compared
with the local PT system using orthogonal regression.1
International sensitivity index (ISI) calibrations need to be
species specific using the three different IRPs—that is,
human (rTF/95, ISI 0.94), rabbit (RBT/90, ISI 1.0), and
bovine (OBT/79, ISI 1.0).
‘‘The WHO prothrombin time standardisation scheme
derives from a mathematical determination of the respon-
siveness of individual prothrombin time test systems’’
The rabbit and human preparations originally calibrated in
19912 and 1995,3 respectively, are mainly used. No provision
was made for their longterm stability monitoring. In a
European Concerted Action on Anticoagulation (ECAA)
study in 2001 reported by Poller et al,4 both these IRPs were
calibrated at 10 centres. The relation between the ISI of the
IRP with results obtained in 1995, reported by Tripodi et al,3 is
examined in our present study to determine whether it has
remained constant.
MATERIALS AND METHODS
Blood was drawn into 105 mmol/litre sodium citrate
(Vacutainer; Becton Dickinson, Oxford, UK), centrifuged,
and plasma transferred into plastic tubes; the tubes were
capped at room temperature and the blood was tested within
six hours.
The 10 ECAA centres calibrating rTF/95 used fresh citrated
plasma from 20 normal controls and 60 patients according to
the WHO protocol. Plasma from each subject was tested in
parallel with rTF/95 and RBT/90.1 Plasma samples were tested
with the two IRPs in a fixed sequence provided to all centres.5
All donors gave informed consent.
STATISTICAL ANALYSIS
The ISI for rTF/95 was derived against RBT/90, and the
imprecision of the calibration line slope was expressed as a
coefficient of variation (CV(b)), according to WHO guide-
lines.1 Only the assumption that the mean log PT of normal
controls lies on the calibration line derived from patients’ PT
values was assessed.6
Between centre ISI variation was measured using CV (%).
Outlying ISIs were detected by means of an algorithm.2 3
A two sample t test was performed to compare the ISI of
rTF/95 in the ECAA study with the mean ISI of the Tripodi
et al study.3 Between centre variations in the ISI for the two
studies were compared (F test).
The prothrombin ratio (PR) for rTF/95, corresponding to a
theoretical international normalised ratio (INR) of 3.0, was
calculated with the mean ISI from the Tripodi et al
calibration.3 This PR was then used to calculate an INR with
the mean ISI obtained in our present study, and the absolute
percentage deviation from a theoretical INR of 3.0 was
determined. Absolute INR deviation exceeding 10% was
deemed clinically relevant.4 7
RESULTS
Tables 1 and 2 show the individual centre results for the 1995
Tripodi et al study,3 and for the later ECAA study, respectively.
In the later study, one centre gave an outlying ISI. After
exclusion of this centre, the ECAA gave a mean ISI of 0.99,
which is significantly different from the mean ISI of 0.94
obtained by Tripodi and colleagues3 (95% confidence interval
for difference in mean ISI, 0.01 to 0.09; two sample t test,
p = 0.009).
The CV(b) of the calibration slope for the ECAA study
ranged from 1.9% to 4.5% (mean CV(b), 3.0%). Six centres
reported a CV(b) within the 3% limit set by the WHO
guidelines.1 For the Tripodi et al study,3 the CV(b) ranged
from 1.8% to 4.0% (mean CV(b), 2.8%). Thirteen centres
reported a CV(b) below 3%.
Abbreviations: CV, coefficient of variation; ECAA, European
Concerted Action on Anticoagulation; INR, international normalised
ratio; IRP, international reference preparation; ISI, international
sensitivity index; PR, prothrombin ratio; PT, prothrombin time; WHO,
World Health Organisation
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No calibration resulted in significant displacement of the
mean log normal PT from the patients only line.
Tables 1 and 2 show the mean INR of the patients’ samples
calculated with the established ISI values for rTF/95 and RBT/
90.
Between centre ISI differences were slightly greater in our
present calibration (ISI range, 0.80–1.05; CV, 7.0%) than in
the first by Tripodi and colleagues3 (ISI range, 0.85–1.05; CV,
5.0%). Between centre variations in the ISI for the two
calibrations were not significantly different (F test, p = 0.2).
A PR of 3.2 gave a theoretical INR of 3.0 with the mean ISI
of 0.94 in the original Tripodi et al report.3 After exclusion of
the outlying centre, this PR gave an INR of 3.2 with the mean
ISI of 0.99 from the ECAA study (6.0% difference from a
theoretical INR of 3.0).
DISCUSSION
It is reassuring that no gross change has occurred in the ISI
relation between the two main WHO reference thromboplas-
tins over the six year interval between the two calibrations.
A small change in the ISI for rTF/95 relative to RBT/90,
similar to the change seen in our present calibration was
noted in a report in 2002,8 but was not significant. The trend
to a slightly greater ISI for rTF/95 relative to RBT/90 reported
here would lead to a small INR bias between thromboplastins
calibrated with these IRPs. However, the INR bias at INR 3.0
is 6%, which is not greater than the accepted 10% level of
clinical relevance.
The average INR of the patients in the first study was
slightly greater than in the second, but there was no
significant correlation between local ISI and mean INR.
This suggests that any differences in ISI were not caused by
different mean patient INR values, and is in agreement with
the mean log PT of normals lying on the line derived only
from the patients’ PT.
‘‘It is reassuring that no gross change has occurred in the
international sensitivity index relation between the two
main WHO reference thromboplastins’’
Although there were differences in centres, technicians,
patient and normal samples, and collection tubes between
the two multicentre calibrations, a change in the physical
Table 1 Multicentre ISI calibration of rTF/95 against RBT/90 reported by Tripodi and colleagues3
Centre N ISI CV(b) Slope of patients only line INR (RBT/90) INR (rTF/95)
1 73 0.85 2.8 0.80 2.94 3.22
2 72 0.97 4.0 1.06 2.75 2.67
3 78 0.99 1.8 1.12 2.79 2.70
4 75 0.94 3.3 0.87 2.78 2.77
5 78 0.95 2.4 0.94 2.59 2.54
6 79 0.96 2.1 0.99 2.74 2.71
7 69 0.92 3.3 1.02 2.66 2.77
8 80 0.88 2.8 0.92 2.43 2.58
9 80 0.94 3.4 0.95 2.72 2.74
10 72 0.93 2.2 0.95 2.86 2.83
11 67 1.05 3.5 1.04 2.56 2.31
12 78 0.90 2.7 0.94 2.62 2.79
13 79 0.94 2.7 0.92 2.43 2.44
14 73 0.98 2.0 1.03 2.75 2.71
15 75 0.95 2.3 1.02 2.87 2.89
16 74 0.92 3.5 0.93 2.41 2.45
17 68 0.96 2.2 0.92 2.90 2.77
18 74 0.87 2.8 0.93 2.40 2.58
19 79 0.99 2.5 1.08 2.62 2.53
Overall 0.94 2.8 0.97 2.67 2.68
CV (%) 5.0 7.9
N is the total number of samples used in each calibration. CV(b) is the coefficient of variation of the calibration slope for healthy subjects plus patients. The mean
INR for the patients’ samples included in the calibration was calculated from RBT/90 and rTF/95 measurements. The bottom row gives the between centre CV of
the ISI and slope of patients only line.
CV, coefficient of variation; INR, international normalised ratio; ISI, international sensitivity index.
Table 2 Multicentre ISI calibration of rTF/95 against RBT/90 performed by the ECAA in 2001
Centre N ISI CV(b) Slope of patients only line INR (RBT/90) INR (rTF/95)
A 75 0.97 3.1 0.95 2.41 2.33
B 73 0.99 2.2 1.08 3.09 2.95
C 70 1.02 2.7 1.17 2.90 2.73
D 76 0.99 3.2 0.97 2.44 2.35
E 73 0.95 1.9 1.00 2.96 2.96
F 78 0.80* 4.5 0.81 2.20 2.51
G 75 0.97 2.3 1.06 2.24 2.21
H 73 1.05 2.7 1.14 2.58 2.37
I 71 1.03 2.8 0.92 2.87 2.56
J 74 0.96 4.5 0.96 2.16 2.14
Overall 0.97 3.0 1.00 2.58 2.51
Between laboratory CV 7.0 10.9
Overall, excluding F 0.99 2.8 1.03 2.63 2.51
Between laboratory CV 3.5 8.6
N is the total number of samples used in each calibration. CV(b) is the coefficient of variation of the calibration slope for healthy subjects plus patients. The mean
INR for the patients, samples included in the calibration was calculated from RBT/90 and rTF/95 measurements.
*Detected as an outlying result.
CV, coefficient of variation; ECAA, European Concerted Action on Anticoagulation; INR, international normalised ratio; ISI, international sensitivity index.
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or chemical properties of rTF/95 or RBT/90 cannot be
excluded as a cause of the difference between the two
calibrations.
RBT/90 will be replaced soon and both rTF/95 and RBT/90
(and OBT/79) should be included in the proposed calibra-
tion.9 Any INR bias between the two routes of calibration
would thus be minimised.
The CVs of the slopes at all centres were acceptable,
all being less than 5%. However, the 3% CV limit may be
too ambitious for a cross species calibration, as shown by
the fact that four centres in the later study exceeded this
figure.
An ongoing programme of stability monitoring is recom-
mended for thromboplastin IRPs. This could be similar to the
10 year study of the British Committee of Standards for
Haematology for the WHO human thromboplastin IRP, BCT/
253.10 Alternatively, multicentre ISI calibrations should be
repeated at four years intervals.
ACKNOWLEDGEMENTS
Additional multicentre study participants: J Conard, Laboratoire
Central D’He´matologie, Hoˆtel-Dieu de Paris, Paris, France; D Dias,
Service Immunotherapia, Hospital de S Joao, 4760 Vila Nova de
Famalicao, Porto, Portugal; N Egberg, Department of Clinical
Chemistry, Karolinska Hospital, Stockholm, Sweden; JA Iriarte,
Instituto de Epidemiologia y Prevencion de Enfermedades
Cardiovasculares, Hospital Civil de Basurto, Bilbao, Spain; I
Kontopoulou-Griva, Anticoagulant Unit, Hippocration General
Hospital, Athens, Greece; B Otridge, Haematology Department,
Mater Misericordiae Hospital, Dublin, Ireland.
We are also grateful to the following scientific staff for their valuable
assistance: G Anthi (Athens, Greece), M Clerici (Milan, Italy), H
Fitzgerald (Dublin, Ireland), MH Horellou (Paris, France), J
Meeuwisse-Braun (Leiden, the Netherlands), EM Norberg and
L So¨derblom (Stockholm, Sweden), K Overgaard (Esbjerg,
Denmark), M Vacas Rius (Bilbao, Spain).
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
L Poller, M Keown, N Chauhan, ECAA Central Facility, Faculty of Life
Sciences, University of Manchester, Manchester M13 9PT, UK
A M H P van den Besselaar, Haemostasis and Thrombosis Research
Centre, Leiden University Medical Centre, 2300 RC Leiden, The
Netherlands
A Tripodi, A Bianchi Bonomi, Haemophilia and Thrombosis Centre,
IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
C Shiach, Department of Haematology, Manchester Royal Infirmary,
Oxford Road, Manchester M13 9WL, UK
J Jespersen, Department for Thrombosis Research, University of
Southern Denmark and Department of Clinical Biochemistry, Ribe
County Hospital, Esbjerg, DK-6700 Denmark
The study was supported by EC Standards, Measurements and Testing
Programme (grant number SMT4-CT98-2269) and an additional
research grant from the Manchester Thrombosis Research Foundation.
Gratitude is expressed to WHO Biologicals for the supply of RBT/90 and
rTF/95 IRP.
Correspondence to: Professor L Poller, ECAA Central Facility, Faculty of
Life Sciences, The University of Manchester, Manchester; ecaa@
manchester.ac.uk
Accepted for publication 29 October 2004
REFERENCES
1 WHO Expert Committee on Biological Standardisation. Guidelines for
thromboplastins and plasma to control oral anticoagulant therapy. World
Health Organ Tech Rep Ser 1999;889:64–93.
2 Van den Besselaar AMHP. Multicenter study of replacement of the
international reference preparation for thromboplastin, rabbit, plain. Thromb
Haemost 1993;70:794–9.
3 Tripodi A, Chantarangkul V, Negri B, et al. International collaborative study
for the calibration of a proposed reference preparation for thromboplastin,
human recombinant, plain. Thromb Haemost 1998;79:439–43.
4 Poller L, Keown M, Chauhan N, et al. Multicentre international sensitivity
index calibration of two types of point-of-care prothrombin time monitor
systems. Br J Haematol 2002;116:844–50.
5 Poller L, Keown M, Chauhan N, et al. Comparison of fresh plasma and whole
blood multicentre ISI calibrations of CoaguChek Mini and TAS PT-NC whole
blood prothrombin time point-of-care monitors. Thromb Haemost
2002;87:859–66.
6 Tomenson JA. A statistician’s independent evaluation. In: Van den
Besselaar AMHP, Lewis SM, Gralnick HR, eds. Thromboplastin calibration and
oral anticoagulant control. Boston: Martinus Nijhoff Publishers, 1984:87–108.
7 Poller L, van den Besselaar AMHP, Jespersen J, et al. The effect of sample size
on fresh plasma thromboplastin ISI determination. Br J Haematol
1999;105:655–63.
8 Van den Besselaar AMHP, Tripodi A. A reassessment of the relationship
between international reference preparations for human and rabbit
thromboplastins. Thromb Haemost 2002;88:459–61.
9 Tripodi A, Poller L, van den Besselaar AMHP, et al. A proposed scheme for
calibration of international reference preparations of thromboplastin for the
prothrombin time. Thromb Haemost 1995;74:1368–9.
10 Poller L, Pulford J, Stevenson KJ, et al. Long term stability studies on the WHO
IRP thromboplastin (human plain BCT/253). Thromb Haemost
1994;72:682–4.
Take home messages
N We carried out a 10 centre calibration to determine the
international sensitivity index (ISI) of rTF/95 relative to
RBT/90, and to assess any international normalised
ratio (INR) bias compared with the original multicentre
calibration
N There was a small change in the ISI for rTF/95, which
would lead to a slight bias in INR for human compared
with rabbit thromboplastins, although at a theoretical
INR of 3.0, this bias is below the accepted 10% level of
clinical relevance
N Ongoing stability monitoring of World Health Organi-
sation thromboplastin international reference prepara-
tions is recommended
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